Prana eyes Phase III for lead asset on Huntington's data
This article was originally published in Scrip
Phase II data for Prana Biotechnology's investigational therapy PBT2 show that it is safe and tolerable, with enough suggestion of clinical efficacy in early to mid-stage Huntington's disease for the company to take it into Phase III. Shares in the firm were up by as much as 24% to $9.10 in trading on Nasdaq on the morning of 18 February.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.